share_log

Wedbush Maintains Neutral on Apellis Pharmaceuticals, Raises Price Target to $67

Benzinga Real-time News ·  Sep 12, 2022 09:48

Wedbush analyst Laura Chico maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Neutral and raises the price target from $55 to $67.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment